title: Preheparin lipoprotein lipase mass is a practical marker of insulin resistance in ambulatory type 2 diabetic patients treated with oral hypoglycemic agents.
abstract: BACKGROUND
  Lipoprotein lipase (LPL) is a key enzyme in the metabolism of triglyceride (TG)-rich lipoproteins. LPL in the preheparin serum (Pr-LPL) mass reflects the insulin sensitivity of diabetic patients (DM) receiving neither insulin nor hypoglycemic agents.
  
  
  METHODS
  To determine whether Pr-LPL mass is a marker of insulin resistance in ambulatory type 2 DM receiving oral hypoglycemic agents, we measured Pr-LPL mass using an enzyme immunoassay in 107 ambulatory DM aged 64.9+/-11.5 y.
  
  
  RESULTS
  Pr-LPL mass was inversely correlated with the homeostasis model assessment of insulin resistance (HOMA-IR) (-0.363, p<0.001), insulin (-0.351, p<0.001), and lnTG (-0.402, p<0.001), and was positively correlated with HDL-C (0.471, p<0.001). The correlation between Pr-LPL mass and HOMA-IR was equally strong in men and women. Despite medications, hypertension, dyslipidemia, and metabolic syndrome were associated with low Pr-LPL mass. Multiple regression analysis revealed that HOMA-IR was the strongest predictor of Pr-LPL mass. Pr-LPL mass remained constant from 07:30 to 17:30 h.
  
  
  CONCLUSIONS
  Pr-LPL mass is a marker of insulin resistance in ambulatory type 2 DM receiving oral hypoglycemic agents, and Pr-LPL mass is stable during the daytime. Therefore, Pr-LPL mass may be more useful than HOMA-IR at diabetes clinics, especially for patients in the postprandial state.
authors.affiliation: Division of Endocrinology and Metabolism, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi, Niigata 951-8510, Japan.
authors.forename: Osamu
authors.initials: O
authors.lastname: Hanyu
authors.forename: Takashi
authors.initials: T
authors.lastname: Miida
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Kosuge
authors.forename: Takako
authors.initials: T
authors.lastname: Ito
authors.forename: Satoshi
authors.initials: S
authors.lastname: Soda
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hirayama
authors.forename: Elfi
authors.initials: E
authors.lastname: Wardaningsih
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Fueki
authors.forename: Konen
authors.initials: K
authors.lastname: Obayashi
authors.forename: Yoshifusa
authors.initials: Y
authors.lastname: Aizawa
mesh_terms: D000553:Ambulatory Care; D015415:Biomarkers / Q000097:blood; D002940:Circadian Rhythm; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006493:Heparin / Q000737:chemistry; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D008071:Lipoprotein Lipase / Q000097:blood* / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight
chemical_list: D015415:Biomarkers; D007004:Hypoglycemic Agents; D006493:Heparin; D008071:Lipoprotein Lipase